Cargando…

PB2166: PRIMARY MYELOFIBROSIS: SERUM LACTATE DEHYDROGENASE AS A PREDICTOR OF EARLY LEUKEMIC PROGRESSION

Detalles Bibliográficos
Autores principales:	Moura, Pedro, Oliveira, Diogo, Ribeiro, Anabela, Carda, José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429664/ http://dx.doi.org/10.1097/01.HS9.0000975424.74329.7e

Ejemplares similares

PB2166: TET ENZYMES PROTECT AGAINST FATAL LYMPHOPROLIFERATION
por: Spoeck, S., et al.
Publicado: (2022)

PB2228: WHAT IS THE UTILITY OF THE MYSEC-PM ON SECONDARY MYELOFIBROSIS RISK STRATIFICATION IN A REAL LIFE SETTING?
por: Moura, Pedro, et al.
Publicado: (2023)

PB2040: LACTATE DEHYDROGENASE IS A PREDICTOR OF THROMBOEMBOLISM, AND THROMBOEMBOLISM IS A PREDICTOR OF DEATH, IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): RESULTS FROM A KOREAN PNH REGISTRY
por: Jang, Jun Ho, et al.
Publicado: (2023)

PB2230: THE ORIGIN IN PRIMARY AND SECONDARY MYELOFIBROSIS: IS THE KEY THE PROGENITOR OR THE MOLECULAR SIGNATURE?
por: Cuadrado, Isabel Montero
Publicado: (2023)

PB2231: AN OVERLOOKED MIMIC? AUTOIMMUNE MYELOFIBROSIS - A SCOPING REVIEW OF THE LITERATURE
por: Riazat-Kesh, Yosef Joseph Rene Amel, et al.
Publicado: (2023)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Korsakova, Natalia, et al.
Publicado: (2023)

PB2056: MYELOFIBROSIS IN PATIENTS OLDER THAN 70 YEARS: IS TREATMENT WITH RUXOLITINIB WORTH IT?
por: Montero, M. I.
Publicado: (2022)

PB2048: EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER STUDY
por: Chen, C., et al.
Publicado: (2022)

PB2203: INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS
por: Junker, Sophia, et al.
Publicado: (2023)

PB2220: ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED
por: Lucijanic, Marko, et al.
Publicado: (2023)

PB2258: MANAGEMENT OF FEBRILE NEUTROPENIA IN LEUKEMIC PATIENTS: A MONOCENTRIC STUDY
por: Boufrikha, W., et al.
Publicado: (2022)

PB2055: A RARE CASE OF HIGH-RISK HEREDITARY THROMBOPHILIA COMBINED WITH PRIMARY MYELOFIBROSIS
por: Khoduleva, S., et al.
Publicado: (2022)

PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY
por: Kaynak, Emine, et al.
Publicado: (2023)

PB1715: UNLEASHING NATURAL KILLER (NK) CELLS TO PROMOTE ANTI-LEUKEMIC IMMUNITY
por: Tsoukala, Ioanna, et al.
Publicado: (2023)

PB2039: CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROM-BOCYTHEMIA，PREFIBROTIC PRIMARY MYELOFIBROSIS, AND OVERT FIBROTIC PRIMARY MYELOFIBROSIS: A CHINESE RETROSPECTIVE STUDY
por: Huang, J., et al.
Publicado: (2022)

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
por: Wang, Shengjie, et al.
Publicado: (2023)

PB2052: CLINICOPATHOLOGIC VARIABLES AFFECTING DISEASE OUTCOME IN PRIMARY MYELOFIBROSIS. A SINGLE CENTER EXPERIENCE.
por: Elkourashy, S., et al.
Publicado: (2022)

PB2177: MULTICENTRE RETROSPECTIVE OBSERVATIONAL STUDY ON PATIENTS WITH MYELOFIBROSIS IN PIEDMONT. ROLE OF INFLAMMATION AND DYSIMMUNITY. MFACTORS STUDY.
por: Bonuomo, Valentina, et al.
Publicado: (2023)

PB2309: EVALUATION OF MORBIMORTALITY FACTORS OF PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
por: Pinto, M. I., et al.
Publicado: (2022)

PB2057: REAL -WORLD OVERALL SURVIVAL OF MYELOFIBROSIS PATIENTS ON RUXOLITINIB – A 6 YEAR ANALYSIS IN ALBANIAN POPULATION
por: Perolla, A., et al.
Publicado: (2022)

PB2196: CLINICAL IMPACT OF NUTRITIONAL STATUS AND NUTRITIONAL MONITORING IN PRIMARY MYELOFIBROSIS PATIENTS: PRELIMINARY RESULTS OF NUTRIMY STUDY
por: Malchiodi, Margherita, et al.
Publicado: (2023)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
por: Mascarenhas, John, et al.
Publicado: (2023)

PB2251: SOMETIMES IT’S ZEBRAS: SUCCESSFUL TREATMENT OF ERYTHROPOIETIC PROTOPORPHYRIA POST PRIMARY MYELOFIBROSIS WITH GIVOSIRAN - A CASE REPORT
por: Catana, Alina, et al.
Publicado: (2023)

PB1857: NRF2 MODULATORS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A POSSIBLE NEW THERAPEUTIC APPROACH
por: Carda #, J. P., et al.
Publicado: (2022)

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)
por: Masarova, Lucia, et al.
Publicado: (2023)

PB1778: PAN-PIM KINASE INHIBITOR PIM447 SHOWS SUPERIOR ANTI-LEUKEMIC EFFECT IN ACUTE ERYTHROID LEUKEMIA
por: Tseng, Chi-Yang, et al.
Publicado: (2023)

PB2051: PRIMARY MYELOFIBROSIS IN YOUNG PATIENTS ≤50 YEARS: CLINICOPATHOLOGICAL CHARACTERISTICS, GENETIC LANDSCAPE AND DISEASE OUTCOME. A SINGLE CENTER EXPERIENCE
por: Elkourashy, S., et al.
Publicado: (2022)

PB2184: IMPACT OF TRANSFUSION BURDEN ON HEALTH-RELATED QUALITY OF LIFE AND FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS: POST HOC ANALYSIS OF SIMPLIFY-1 AND -2
por: Mesa, Ruben, et al.
Publicado: (2023)

PB2142: SERUM OSTEOCALCIN AS A PREDICTOR FOR THE RISK OF DENOSUMAB AND BISPHOSPHONATE INDUCED HYPOCALCEMIA IN MYELOMA PATIENTS WITH HYPERCALCEMIA
por: Ding, Yuehua, et al.
Publicado: (2023)

PB1841: NUCLEOLIN INTERACTS WITH NUCLEOPHOSMIN AS A PREDICTOR OF PROGNOSIS IN ACUTE MYELOBLASTIC LEUKEMIA
por: Pereira, Marta, et al.
Publicado: (2023)

PB2206: PROGRESSION FACTORS OF MYELOFIBROSIS BASED ON CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROMBOCYTHEMIA: A CHINES TWO-CENTER RETROSPECTIVE STUDY
por: Xiang, Danhong, et al.
Publicado: (2023)

PB2079: LACTATE DECREASES BORTEZOMIB SENSITIVITY AND PREDICTS POOR CLINICAL OUTCOMES OF MULTIPLE MYELOMA
por: MA, Naya, et al.
Publicado: (2023)

PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF
por: Kuykendall, Andrew, et al.
Publicado: (2023)

PB1759: RETAINED FUNCTIONAL NORMAL AND/OR PRE-LEUKEMIC HSCS IN THE BONE MARROW ARE ASSOCIATED TO GOOD PROGNOSIS IN DNMT3AMUTNPM1MUT AML PATIENTS
por: Donato, Elisa, et al.
Publicado: (2023)

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
por: Palacio, Melisa, et al.
Publicado: (2023)

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT-I AND -II TRIALS
por: Al-Ali, Haifa Kathrin, et al.
Publicado: (2023)

PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
por: Koster, K.-L., et al.
Publicado: (2022)

PB2204: HIGH SERUM FERRITIN AT INITIAL DIAGNOSIS IS A PREDICTOR OF BONE MARROW FIBROSIS IN PH NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Leone, Aldo, et al.
Publicado: (2023)

PB1866: RESPONSE TO NOVEL ANTI CD20 ANTIBODY AND BCL2 INHIBITOR IN A PATIENT WITH CLL AND MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS ASSOCIATED WITH LEUKEMIC KIDNEY INFILTRATION AND REVIEW OF LITERATURE
por: Goanta, J. G., et al.
Publicado: (2022)

PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)
por: Mascarenhas, John, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_440cghri8ml9hm3numk52r704h